Search Within

Joachim Yahalom

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (10)
  2. Journal Article (5)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (16)
  2. Department of Medicine (16)
  3. GSK Faculty (16)
  4. Hematologic Malignancies, Division of (16)
  5. Human Oncology and Pathogenesis Program (16)
  6. Radiation Oncology, Department of (16)

More Groups

People
  1. Santosha Vardhana (15)
  2. Alison Moskowitz (14)
  3. Andrew Zelenetz (13)
  4. Philip Caron (13)
  5. Heiko Schoder (12)
  6. Paul Hamlin (12)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (5)
  4. 2022 (1)
  5. 2021 (1)
  6. 2020 (2)

More Years

Publications
  1. Blood (6)
  2. Hematological Oncology (3)
  3. Journal of Clinical Oncology (3)
  4. Biology of Blood and Marrow Transplantation (2)
  5. Blood Advances (1)
  6. Blood Cancer Journal (1)
Publishers
  1. American Society of Hematology (7)
  2. American Society of Clinical Oncology (3)
  3. Wiley Blackwell (3)
  4. Elsevier Inc. (2)
  5. Nature Publishing Group (1)

Results (16)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S. A.; Ames, A.; Biggar, E.; Moskowitz, A. J.; Batlevi, C. L.; Caron, P.; Hamilton, A. M.; Moskowitz, C. H.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL)
    Meeting Abstract

    Sermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes of relapsed and refractory primary mediastinal (thymic) large B cell lymphoma treated with second-line therapy and intent to transplant
    Journal Article

    Vardhana, S.; Hamlin, P. A.; Yang, J.; Zelenetz, A.; Sauter, C. S.; Matasar, M. J.; Ni, A.; Yahalom, J.; Moskowitz, C. H.
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: Long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease
    Journal Article

    Goldberg, J. D.; Linker, A.; Kuk, D.; Ratan, R.; Jurcic, J.; Barker, J. N.; Castro-Malaspina, H.; Giralt, S.; Hsu, K.; Jakubowski, A. A.; more...
    Biology of Blood and Marrow Transplantation (2013)

    Fulltext@MSK | Save